Published in final edited form as:

Exp Cell Res. 2016 April 10; 343(1): 82–88. doi:10.1016/j.yexcr.2016.02.003.

The involvement of mutant Rac1 in the formation of invadopodia in cultured melanoma cells

Or-Yam Revach, Sabina E Winograd-Katz, Yardena Samuels, and Benjamin Geiger*

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel

Abstract

In this article, we discuss the complex involvement of a Rho-family GTPase, Rac1, in cell migration and in invadopodia-mediated matrix degradation. We discuss the involvement of invadopodia in invasive cell migration, and their capacity to promote cancer metastasis. Considering the regulation of invadopodia formation, we describe studies that demonstrate the role of Rac1 in the metastatic process, and the suggestion that this effect is attributable to the capacity of Rac1 to promote invadopodia formation. This notion is demonstrated here by showing that knockdown of Rac1 in melanoma cells expressing a wild-type form of this GTPase, reduces invadopodia-dependent matrix degradation. Interestingly, we also show that excessive activity of Rac1, displayed by the P29S, hyperactive, “fast cycling” mutant of Rac1, which is present in 5–10% of melanoma tumors, inhibits invadopodia function. Moreover, knockdown of this hyperactive mutant enhanced matrix degradation, indicating that excessive Rac1 activity by this mutant can negatively regulate invadopodia formation and function.

Keywords

Invadopodia; Cell adhesion; Metastasis; Melanoma; Cell invasion; Cellular mechanics; Rac1

1 Invadopodia-mediated cancer invasion

Invadopodia are actin-based protrusions of the plasma membrane that penetrate into the extracellular matrix (ECM), and enzymatically degrade it [1–3]. They belong to a family of structures, collectively known as invadosomes [4], that facilitate cell invasion through tissues. This process occurs under specific physiological conditions such as wound repair, embryogenesis, and cell differentiation, as well as under pathological conditions such as pathogen infection or cancer metastasis [5].

Invadopodia are unique adhesion structures whose activities – invasion, adhesion and matrix degradation – are each regulated and implemented by a set of multiple proteins. Coordination of their functions occurs on both spatial and temporal levels, controlled by a mechanism that can be referred to as a highly coordinated “grip-soften-push” mechanism [6].

*Corresponding author. benny.geiger@weizmann.ac.il (B. Geiger).

Invadopodia attach to the ECM via their adhesion domain, a ring-shaped structure surrounding the actin core [7–9]. This ring contains transmembrane integrin receptors and various adhesion proteins such as vinculin, paxillin, zyxin, ILK and Hic-5, as well as GTPases and proteases [9]. The adhesion process is critical for invadopodia function, yet it is commonly a transient state [7,9], which is followed by matrix degradation by a variety of proteases belonging to the metalloproteinase (MMPs), ADAM, and serine protease families [2,5,10,11]. The membrane-bound protease, MT1-MMP (or MMP14), functions as a master regulator of invadopodia development [10,12], whose recruitment promotes invadopodia maturation [3] and activation of the soluble MMPs, MMP9 and MMP2 [11,13].

The actin core arises out of the adhesion process, starting when receptor tyrosine kinases such as the EGF receptor are activated [14,15]. This signaling event, in turn, triggers the activation of c-src [16–19,3–6], PKC kinases [20–23] and, eventually, the adaptor protein TKS5 [24], which plays a key role in the nucleation and formation of the actin core bundle. TKS5 can then bind to PtdIns(3,4)P₂ at the plasma membrane, enhancing the recruitment of actin regulators, such as NCK1, to the membrane [3]. This signaling cascade, which leads to actin polymerization in invadopodia cores, is regulated by small Rho-family GTPases, and drives actin polymerization by the Arp2/3 complex [25–28]. Arp 2/3-driven actin nucleation is promoted by the severing activity of cofilin [29–31]. The actin bundle thus formed is further stabilized and is mostly CDC42-dependent [2,14], which can directly activate the N-WASP-WIP complex; this, in turn, is mechanically reinforced by cortactin [5] and fascin [25,32,33], producing a stable “invasive protrusion” that pushes against the ventral cell membrane, promoting its penetration into the ECM [5,12,14,20,34–36].

The main cause of cancer mortality is the process of metastasis. In order to metastasize, cancer cells must acquire the ability to breach the surrounding extracellular matrix (by various modes of cell invasion [37]), then disperse and penetrate into the surrounding normal tissue, as well as into neighboring blood vessels and lymphatics (by intra- and extravasation) [38]. The invasive potential of cancer cells is mostly correlated with their ability to form invadopodia [39]. This correlation has been demonstrated in many types of cancer cells, among them primary glioma [40], breast cancer [41], and bladder cancer [42].

Modulation of invadopodia components was shown to inhibit cancer cell invasion in *in vitro* models, and cancer metastasis in mice. For example, while overexpression of cortactin in breast cancer cells led to an increase in bone metastatic potential, overexpression of a phosphorylation-deficient mutant cortactin reduced the cell’s metastatic potential [43]. Furthermore, expression of various TKS5 adaptor isoforms was shown to regulate the metastatic potential of lung adenocarcinoma in a mouse model: While the short TKS5 isoform inhibits metastasis, the long one promotes it [44].

2 Rho family GTPases and their role in invadopodia-mediated cancer invasion

Studies addressing the regulation of invadopodia formation and function focused much attention around the involvement of Rho-family GTPases in the number and activity of invadopodia in cancer cells. Activation of Rho GTPases was shown to drive invadopodia

development and invasion in epithelial ovarian cancer cells [45]. Over-activation of small GTPases through upregulation of intracellular GTP levels was also shown to enhance the ability of melanoma cells to invade and metastasize [46].

Though Rho family GTPases were shown to be involved in invadopodia formation and function [2], until now, most such studies have focused primarily on the small Rho-family GTPase CDC42 [2,28]. Expression of constitutively active CDC42 in RPMI17951 melanoma cells increased formation of invadopodia, while expression of dominant negative RAC1 resulted in a diffuse type of matrix degradation [47]. In glioma cells, inhibition of RAC1 reduced invadopodia formation [48], and in MCF10A cells, such inhibition reduced matrix degradation. Based on such results, it was proposed that RAC1 has a role in invadopodia formation and invasive function, although the mechanisms underlying this process are still poorly understood.

Another instance of actin reorganization occurs during cell migration [37]. This process is mainly regulated by the small GTPases RAC1 and Cdc42 [37], which play an important role in driving the development of lamellipodial and filopodial extensions at the cell's leading edge during cell migration, and are known to promote cancer invasion [49,50].

During the past decade, multiple melanoma oncogenes were identified, several of which were successfully targeted pharmacologically, using small molecular-weight drugs [51,52]. Among them, the small GTPase RAC1, mutated at position 29, was shown to be associated with 5–10% of all melanomas. This mutant was shown to be an active form (“fast-cycling”) of RAC1 [53,54], suggesting that excessive Rac1 activity might promote melanoma malignancy. The P29S mutation is located in the switch I region of RAC1, known to be a conserved regulatory element of the GTPase superfamily, important for nucleotide binding and, therefore, interactions with downstream effectors [54–56]. RAC1-P29S was shown to bind more GTP, as well as downstream effectors such as PAK1 and MLK3 [53,54]. It also induces ERK phosphorylation, cell proliferation, membrane ruffling, and transwell migration in normal cells [54,57]. The general mode of action of Rac1, and its P29S mutant, are shown in Fig. 1A.

Due to the importance of RAC1 in cytoskeletal regulation during migration, primarily through its ability to stimulate actin nucleation at the leading edge [53,58] and its newly discovered association with metastatic melanoma, we aimed to characterize the effects of RAC1-P29S on cell adhesion and cytoskeletal organization in melanoma. We specifically focused on the involvement of the RAC1-P29S mutation in the regulation of invadopodia formation and organization in metastatic melanoma cells.

3 RAC1-P29S is an active form of RAC1 in cells that harbor the mutation

To study the effects of RAC1-P29S on adhesion, cytoskeletal organization, and invadopodia formation and function in melanoma cells, we used four melanoma cell lines, two of which express wild-type RAC1 (A375 and 31T) and two that harbor the RAC1-P29S mutation (104T and 83T). From the available Sanger sequencing information, shown in Fig. 1B, we know that one of the mutant cell lines is a homozygote for the mutation (83T), and the other

(104T) is a heterozygote (Fig. 1B). To test if the zygosity affects RAC1 activity in the cells, both mutants were analyzed using the RAC1 activation assay (Fig. 1C). As shown, the homozygous mutant 83T demonstrated considerably stronger Rac1 activity than the heterozygous mutant, when normalized to the total Rac1 protein present in the cell. This was true both at basal levels of Rac1 activity, and after stabilization of the active Rac1 form by the addition of GTP γ S, a non-hydrolysable form of GTP (Fig. 1C). Notably, Rac1 activity levels were very low in the wild-type Rac1 melanoma lines, A375 and 31T (data not shown). These results suggest that the zygosity of RAC1-P29S correlates with RAC1 activation in the cells, strengthening the claim that the mutant encodes for an active RAC1, as previously shown [57].

4 RAC1-P29S drives lamellipodia formation in cells that harbor the mutation

To test the activation of RAC1-P29S at the level of cytoskeletal function, the two RAC1-WT cell lines (A375 and 31T) and the two mutant cell lines (104T and 83T) were monitored for over 24 h by phase contrast, live-cell microscopy (Fig. 2A and Supplementary Movie 1). Both mutant cells formed multiple, rounded lamellipodia per cell, and kept their migratory phenotype throughout the assessment. The migratory behavior of the mutant cells was distinctly different from that of the WT cells, which were more polarized and displayed fewer lamellipodia (Fig. 2A and Supplementary Movie 1).

To verify that lamellipodia formation in the mutant cells is due to RAC1 activity, RAC1 was knocked down in both the 104T mutant cells and the A375 WT cells (Fig. 2B; 104T and A375), and the cells were followed for 24 h using time-lapse microscopy (Fig. 2C, and Supplementary Movie 2). Both WT and mutant RAC1 mutant cells displayed reduced motility upon RAC1 knockdown (siRAC1), compared to control siRNA (siCON). In the mutant 104T cells, treatment with RAC1 siRNA led to a gradual loss of the lamellipodia phenotype, and over time, the cells became polarized and less motile (Fig. 2C, and Supplementary Movie 2). In comparison, control cells (siCON) kept their migratory phenotype throughout the period of monitoring.

5 RAC1-P29S negatively regulates invadopodia function in melanoma cells

As RAC1 is known to be involved in actin remodeling processes, we tested the capacity of the RAC1-P29S mutation to affect invadopodia formation and function. To this end, we knocked down RAC1 by siRNA in the two WT (A375, 31T) and two mutant RAC1 cell lines (104T, 83T) (Fig. 2B), and analyzed invadopodia formation and function using a gelatin degradation assay.

To our surprise, Rac1 knockdown led to a differential effect on invadopodia-mediated matrix degradation in the WT and mutant cells. Knockdown of Rac1 in WT cells caused a twofold reduction in matrix degradation in both cell types (A375 and 31T) (Fig. 3A and B), while knockdown of Rac1 in the mutant cell lines (104T and 83T), caused a dramatic elevation in

invadopodia function (Fig. 4A and B). Notably, the effect of increased invadopodia function in 83T cells that harbor a homozygous P29S mutation was consistently stronger than that seen in the 104T cells that harbor a heterozygous P29S mutation (Fig. 4A and B), suggesting that WT-RAC1 and P29S-RAC1 regulate invadopodia function in opposite ways.

In addition, it would appear that the overall effect of RAC1 on invadopodia occurs downstream of core formation, since the number of invadopodia-forming cells was similar in control (siCON) and knockdown (siRAC1) in both WT and the heterozygous RAC1-P29S mutant cells. Interestingly, in the homozygous mutant cell line 83T, RAC1-P29S showed a clear capacity to negatively regulate not only invadopodia matrix degradation ability, but also the prominence of invadopodia-forming cells (Fig. 5).

In conclusion, we show here that Rac1 can serve as a potent regulator of invasive cell migration and invadopodia-dependent matrix degradation. Interestingly the effects of the WT Rac1 are quite different from those of the mutant Rac1. As shown here, Rac1 activity in A375 and 31T cells is rather low, compared to that of the mutated 104T and 83T cells, and this difference is manifested in the higher capacity of the mutant to develop lamellipodia and migrate. Surprisingly, and potentially most interesting, is our observation that the hyperactive mutated form, Rac1-P29S, unlike WT Rac1, suppresses matrix degradation while enhancing lamellipodial extension, raising the possibility that the WT and mutant forms of Rac1 operate along different downstream cytoskeletal elements, and possibly signaling pathways. The significance of these differences for understanding the tumorigenic properties of the hyperactive mutant remains to be unraveled.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The research of melanoma migration and invasion is supported by the Israel Science Foundation-3001/13 (BG) Israel Science Foundation-1604/13 and 877/13 (YS), the ERC (StG-335377), U-H2020-ERC-2015-PoC (712216) (YS). BG is the incumbent of the Erwin Neter Chair in Cell and Tumor Biology. YS is the incumbent of the Knell Family Professorial Chair.

References

- [1]. Gimona M, Buccione R, Courtneidge SA, Linder S. Assembly and biological role of podosomes and invadopodia. *Curr Opin Cell Biol.* 2008; 20:235–241. [PubMed: 18337078]
- [2]. Linder S. The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. *Trends Cell Biol.* 2007; 17:107–117. [PubMed: 17275303]
- [3]. Murphy DA, Courtneidge SA. The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function. *Nat Rev Mol Cell Biol.* 2011; 12:413–426. [PubMed: 21697900]
- [4]. Linder S, Wiesner C, Himmel M. Degrading devices: invadosomes in proteolytic cell invasion. *Annu Rev Cell Dev Biol.* 2011; 27:185–211. [PubMed: 21801014]
- [5]. Caldieri G, Ayala I, Attanasio F, Buccione R. Cell and molecular biology of invadopodia. *Int Rev Cell Mol Biol.* 2009; 275:1–34. [PubMed: 19491051]
- [6]. Revach OY, Geiger B. The interplay between the proteolytic, invasive, and adhesive domains of invadopodia and their roles in cancer invasion. *Cell Adhes Migration.* 2014; 8:215–225.

- [7]. Branch KM, Hoshino D, Weaver AM. Adhesion rings surround invadopodia and promote maturation. *Biol Open*. 2012; 1:711–722. [PubMed: 23213464]
- [8]. Pignatelli J, Tumbarello DA, Schmidt RP, Turner CE. Hic-5 promotes invadopodia formation and invasion during TGF-beta-induced epithelial-mesenchymal transition. *J Cell Biol*. 2012; 197:421–437. [PubMed: 22529104]
- [9]. Revach OY, Weiner A, Rechav K, Sabanay I, Livne A, Geiger B. Mechanical interplay between invadopodia and the nucleus in cultured cancer cells. *Sci Rep*. 2015; 5:9466. [PubMed: 25820462]
- [10]. Buccione R, Caldieri G, Ayala I. Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix. *Cancer Metastasis Rev*. 2009; 28:137–149. [PubMed: 19153671]
- [11]. Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L, Yang J. Twist1-induced invadopodia formation promotes tumor metastasis. *Cancer Cell*. 2011; 19:372–386. [PubMed: 21397860]
- [12]. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. *Cancer Res*. 2006; 66:3034–3043. [PubMed: 16540652]
- [13]. Nakahara H, Howard L, Thompson EW, Sato H, Seiki M, Yeh Y, Chen WT. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. *Proc Natl Acad Sci USA*. 1997; 94:7959–7964. [PubMed: 9223295]
- [14]. Yamaguchi H, Lorenz M, Kempiak S, Sarmiento C, Coniglio S, Symons M, Segall J, Eddy R, Miki H, Takenawa T, Condeelis J. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. *J Cell Biol*. 2005; 168:441–452. [PubMed: 15684033]
- [15]. Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. *Biochim Biophys Acta*. 2007; 1773:642–652.
- [16]. Tarone G, Cirillo D, Giancotti FG, Comoglio PM, Marchisio PC. Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. *Exp Cell Res*. 1985; 159:141–157. [PubMed: 2411576]
- [17]. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. *Oncogene*. 2004; 23:7957–7968. [PubMed: 15489913]
- [18]. Kelley LC, Ammer AG, Hayes KE, Martin KH, Machida K, Jia L, Mayer BJ, Weed SA. Oncogenic Src requires a wild-type counterpart to regulate invadopodia maturation. *J Cell Sci*. 2010; 123:3923–3932. [PubMed: 20980387]
- [19]. Oberfell A, Eto K, Mocsai A, Buensuceso C, Moores SL, Brugge JS, Lowell CA, Shattil SJ. Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton. *J Cell Biol*. 2002; 157:265–275. [PubMed: 11940607]
- [20]. Bowden ET, Barth M, Thomas D, Glazer RI, Mueller SC. An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. *Oncogene*. 1999; 18:4440–4449. [PubMed: 10442635]
- [21]. Destaing O, Block MR, Planus E, Albiges-Rizo C. Invadosome regulation by adhesion signaling. *Curr Opin Cell Biol*. 2011; 23:597–606. [PubMed: 21550788]
- [22]. Gatesman A, Walker VG, Baisden JM, Weed SA, Flynn DC. Protein kinase Calpha activates c-Src and induces podosome formation via AFAP-110. *Mol Cell Biol*. 2004; 24:7578–7597. [PubMed: 15314167]
- [23]. Rodriguez EM, Dunham EE, Martin GS. Atypical protein kinase C activity is required for extracellular matrix degradation and invasion by Src-transformed cells. *J Cell Physiol*. 2009; 221:171–182. [PubMed: 19492416]
- [24]. Courtneidge SA. Cell migration and invasion in human disease: the Tks adaptor proteins. *Biochem Soc Trans*. 2012; 40:129–132. [PubMed: 22260678]
- [25]. Gross SR. Actin binding proteins: their ups and downs in metastatic life. *Cell Adhes Migration*. 2013; 7:199–213.

- [26]. Martinez-Quiles N, Rohatgi R, Anton IM, Medina M, Saville SP, Miki H, Yamaguchi H, Takenawa T, Hartwig JH, Geha RS, Ramesh N. WIP regulates N-WASP-mediated actin polymerization and filopodium formation. *Nat Cell Biol.* 2001; 3:484–491. [PubMed: 11331876]
- [27]. Hoshino D, Branch KM, Weaver AM. Signaling inputs to invadopodia and podosomes. *J Cell Sci.* 2013; 126:2979–2989. [PubMed: 23843616]
- [28]. Albiges-Rizo C, Destaing O, Fourcade B, Planus E, Block MR. Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions. *J Cell Sci.* 2009; 122:3037–3049. [PubMed: 19692590]
- [29]. Oser M, Yamaguchi H, Mader CC, Bravo-Cordero JJ, Arias M, Chen X, Desmarais V, van Rheenen J, Koleske AJ, Condeelis J. Cortactin regulates cofilin and N-WASP activities to control the stages of invadopodium assembly and maturation. *J Cell Biol.* 2009; 186:571–587. [PubMed: 19704022]
- [30]. Sibony-Benjamin H, Gil-Henn H. Invadopodia: the leading force. *Eur J Cell Biol.* 2012; 91:896–901. [PubMed: 22633185]
- [31]. Bravo-Cordero JJ, Magalhaes MA, Eddy RJ, Hodgson L, Condeelis J. Functions of cofilin in cell locomotion and invasion. *Nat Rev Mol Cell Biol.* 2013; 14:405–415. [PubMed: 23778968]
- [32]. Li A, Dawson JC, Forero-Vargas M, Spence HJ, Yu X, Konig I, Anderson K, Machesky LM. The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. *Curr Biol.* 2010; 20:339–345. [PubMed: 20137952]
- [33]. Jayo A, Parsons M. Fascin: a key regulator of cytoskeletal dynamics. *Int J Biochem Cell Biol.* 2010; 42:1614–1617. [PubMed: 20601080]
- [34]. Baldassarre M, Ayala I, Beznoussenko G, Giacchetti G, Machesky LM, Luini A, Buccione R. Actin dynamics at sites of extracellular matrix degradation. *Eur J Cell Biol.* 2006; 85:1217–1231. [PubMed: 17010475]
- [35]. Clark ES, Whigham AS, Yarbrough WG, Weaver AM. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. *Cancer Res.* 2007; 67:4227–4235. [PubMed: 17483334]
- [36]. Schoumacher M, Goldman RD, Louvard D, Vignjevic DM. Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. *J Cell Biol.* 2010; 189:541–556. [PubMed: 20421424]
- [37]. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. *Nat Rev Cancer.* 2003; 3:362–374. [PubMed: 12724734]
- [38]. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. *Cell.* 2011; 147:275–292. [PubMed: 22000009]
- [39]. Yamaguchi H. Pathological roles of invadopodia in cancer invasion and metastasis. *Eur J Cell Biol.* 2012; 91:902–907. [PubMed: 22658792]
- [40]. Stylli SS, Kaye AH, Lock P. Invadopodia: at the cutting edge of tumour invasion. *J Clin Neurosci: Off J Neurosurg Soc Australasia.* 2008; 15:725–737.
- [41]. Ben-Chetrit N, Chetrit D, Russell R, Korner C, Mancini M, Abdul-Hai A, Itkin T, Carvalho S, Cohen-Dvashi H, Koestler WJ, Shukla K, et al. Synaptotagmin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. *Sci Signal.* 2015; 8:ra7. [PubMed: 25605973]
- [42]. Sutoh Yoneyama M, Hatakeyama S, Habuchi T, Inoue T, Nakamura T, Funyu T, Wiche G, Ohya C, Tsuboi S. Vimentin intermediate filament and plectin provide a scaffold for invadopodia, facilitating cancer cell invasion and extravasation for metastasis. *Eur J Cell Biol.* 2014; 93:157–169. [PubMed: 24810881]
- [43]. Li Y, Tondravi M, Liu J, Smith E, Haudenschild CC, Kaczmarek M, Zhan X. Cortactin potentiates bone metastasis of breast cancer cells. *Cancer Res.* 2001; 61:6906–6911. [PubMed: 11559568]
- [44]. Li CM, Chen G, Dayton TL, Kim-Kiselak C, Hoersch S, Whittaker CA, Bronson RT, Beer DG, Winslow MM, Jacks T. Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. *Genes Dev.* 2013; 27:1557–1567. [PubMed: 23873940]

- [45]. Semprucci E, Tocci P, Cianfrocca R, Sestito R, Caprara V, Vegliione M, Castro VD, Spadaro F, Ferrandina G, Bagnato A, Rosano L. Endothelin A receptor drives invadopodia function and cell motility through the beta-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. *Oncogene*. 2015
- [46]. Wawrzyniak JA, Bianchi-Smiraglia A, Bshara W, Mannava S, Ackroyd J, Bagati A, Omilian AR, Im M, Fedtsova N, Miecznikowski JC, Moparthy KC, et al. A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion. *Cell Rep*. 2013; 5:493–507. [PubMed: 24139804]
- [47]. Nakahara H, Otani T, Sasaki T, Miura Y, Takai Y, Kogo M. Involvement of Cdc42 and Rac small G proteins in invadopodia formation of RPMI7951 cells. *Genes Cells*. 2003; 8:1019–1027. [PubMed: 14750956]
- [48]. Chuang YY, Tran NL, Rusk N, Nakada M, Berens ME, Symons M. Role of synaptojanin 2 in glioma cell migration and invasion. *Cancer Res*. 2004; 64:8271–8275. [PubMed: 15548694]
- [49]. Rathinam R, Berrier A, Alahari SK. Role of Rho GTPases and their regulators in cancer progression. *Front Biosci*. 2011; 16:2561–2571.
- [50]. Chen L, Zhang JJ, Huang XY. cAMP inhibits cell migration by interfering with Rac-induced lamellipodium formation. *J Biol Chem*. 2008; 283:13799–13805. [PubMed: 18353776]
- [51]. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. *Nat Rev Cancer*. 2012; 12:349–361. [PubMed: 22475929]
- [52]. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. *Genes Dev*. 2012; 26:1131–1155. [PubMed: 22661227]
- [53]. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, et al. A landscape of driver mutations in melanoma. *Cell*. 2012; 150:251–263. [PubMed: 22817889]
- [54]. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. *Nat Genet*. 2012; 44:1006–1014. [PubMed: 22842228]
- [55]. Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. *J Cell Sci*. 2005; 118:843–846. [PubMed: 15731001]
- [56]. Hakoshima T, Shimizu T, Maesaki R. Structural basis of the Rho GTPase signaling. *J Biochem*. 2003; 134:327–331. [PubMed: 14561717]
- [57]. Davis MJ, Ha BH, Holman EC, Halaban R, Schlessinger J, Boggon TJ. RAC1P29S is a spontaneously activating cancer-associated GTPase. *Proc Natl Acad Sci USA*. 2013; 110:912–917. [PubMed: 23284172]
- [58]. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. *Annu Rev Cell Dev Biol*. 2005; 21:247–269. [PubMed: 16212495]

Fig. 1.

RAC1-P29S is an active form of RAC1 in cells that harbor the mutation. (A) A schematic drawing depicting the mode of Rac1-mediated signaling, including the activation of the molecule by exchange factors (GEFs), replacing bound GDP with GTP, and its deactivation by Rac-GTPase-activating proteins (GAPs). The active form of Rac1, in turn, is responsible for multiple cellular processes, including regulation of cell growth and survival (e.g., via stimulation of MAP kinases and NFκB) and modulation of cytoskeletal organization (e.g., via activation of the WAVE1-Arp2/3 pathway), which enhances cell migration, invasion and metastasis. At the bottom, a scheme of the Rac1 molecule is presented, highlighting the main domains of the molecule, and pointing to the position of the P29S mutation within the Switch I domain. (B) Sanger sequencing chromatogram showing the zygosity of the 104T and 83T cells. A normal Rac1 chromatogram is shown for comparison. Red arrow indicates the C > T mutation leading to the P29 > S amino acid change in the Rac1 protein (C) RAC1 activation assay. 104T and 83T cells were cultured for 24 hours prior to lysis. Lysates were precipitated using PDB-PAK beads; a small amount was set aside for use as a loading control. Each sample was split into two, and 0.1 mM GTPγS was added to one of the samples.

Fig. 2. RAC1-P29S drives lamellipodia formation in cells that harbor the mutation. (A) Snapshots of time-lapse, phase contrast microscopy of 104T, 83T (RAC1-P29S), and 31T, A375 (RAC1-WT) cells. The cells were plated on fibronectin-coated, glass-bottom dishes and cultured for 6 h, to enable cell spreading. Scale bar: 100 μ m (Supplementary Movie 1). (B) Western blot analysis of RAC1 levels in control (siCON), or RAC1 knockdown (siRAC1) in 83T, 104T, 31T and A375 cells. (C) First and last time point of time-lapse, phase contrast microscopy of control (siCON) versus RAC1 knockdown (siRAC1) of 104T and A375 cells. The cells were plated on fibronectin-coated, glass-bottom dishes and cultured for 6 h, to enable cell spreading. Cells were then imaged every 5 min for 24 h (Supplementary Movie 2). Magnification as in A.

Fig. 3.

RAC1 enhances invadopodia function in melanoma cells WT for Rac1. (A) Representative gelatin degradation assay of control (siCON) and RAC1 knockdown (siRAC1) in A375 and 31T (WT) cells. Cells were cultured on fluorescently labeled gelatin for 6 h. Cells were then fixed and stained for actin (as invadopodia marker), and DAPI and gelatin degradation were analyzed. Scale bar: 20 μ m. (B) Invadopodia function analysis of control (siCON) versus RAC1 knockdown (siRAC1) in A375 and 31T (WT) cells. Invadopodia function was quantified using ImageJ software as gelatin degradation area/cell (μ m²) using ImageJ software, and was normalized to the control (percentages)

Fig. 4. RAC1-P29S negatively regulates invadopodia function in melanoma cells. (A) Representative experiment of gelatin degradation assay of control (siCON) and RAC1 knock down (siRAC1) in 104T and 83T cells (RAC1-P29S). Scale bar 20 μ m. (B) Invadopodia function analysis, of control versus RAC1 knock down 104T and 83T cells. Invadopodia function was quantified as gelatin degradation area/cell (μ m²) using ImageJ software, and was normalized to the control (percentages).

Fig. 5.

Effect of Rac1 knockdown on the percentage of invadopodia-forming cells, in cells harboring the Rac1-P29S mutation (104T and 83T) or in cells wild-type for Rac1 (A375 and 31T). The number of invadopodia-forming cells was counted manually in the experiments described in Figs. 3 and 4. As shown, Rac1 knockdown had no effect on the percentage of invadopodia-forming cells in the 31T and A375 lines (both expressing WT Rac1), as well as in the mutant 104T line, suggesting that the effects of the knockdown on the total matrix degradation activity are mostly attributable to the effect on the degradation by individual cells. In the case of the mutant 83T cells, part of the enhancement is attributable to the increase in the number of invadopodia-forming cells (~2 fold).